Intellia to stop work on rare disease therapy, lay off staff
The CRISPR gene editing company will reduce its workforce by 27% over the course of the year as it discontinues a treatment for alpha-1 antitrypsin deficiency.
FierceBiotech12d
4DMT tosses 2 programs, halts funds for 3 others as it zeroes in on latest-stage clinical gene therapy
4D Molecular Therapeutics is axing two clinical programs and cutting off funds for three other assets, with resources to be ...
pharmaphorum1d
Sanofi snaps up Inhibrx and its rare disease drug for $2.2bn
France’s Sanofi – a major player in the rare disease category – is offering ... than current therapies for the disease, based on alpha-1 antitrypsin protein from the plasma of healthy ...
David Lynch shared emphysema diagnosis months before his death: Symptoms, causes and more
Although no cause of death or further details were given, the news comes months after Lynch announced he had been living with ...
Intellia cuts 27% of workforce as it eyes commercial launch
Intellia Therapeutics Inc. is shedding employees and paring down its pipeline as it transforms from a late-stage development ...
Business Insider10d
Mereo BioPharma Provides Update on Lead Clinical Programs
Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025 Alvelestat, for Alpha-1 Antitrypsin Deficiency-associated Lung Disease, ...
Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts
More Than 40 Adult Sickle Cell Disease Patients Now Enrolled in BEACON Trial of BEAM-101; Beam Expects to Dose 30 Patients and Present Updated ...